共 8 条
A Comparison of Coagulation Function in Patients Receiving Aspirin and Cefoperazone-Sulbactam With and Without Vitamin K1 : A Retrospective, Observational Study
被引:14
|作者:
Wu, Shuxie
[1
]
Wu, Gao
[2
]
Wu, Hanbin
[3
]
机构:
[1] Fudan Univ, Hosp Obstet & Gynecol, Shanghai, Peoples R China
[2] Naval Mil Med Univ, Dept Pharm, Affiliated Hosp 1, Shanghai, Peoples R China
[3] Tongji Univ, Shanghai East Hosp, Clin Pharm, Sch Med, 150 Jimo Rd, Shanghai 200120, Peoples R China
关键词:
aspirin;
bleeding;
cefoperazone-sulbactam;
coagulation function;
PT prolongation;
vitamin K;
K SUPPLEMENTATION;
THROMBOCYTOPENIA;
HYPOPROTHROMBINEMIA;
FIBRINOLYSIS;
SALICYLATE;
ACID;
D O I:
10.1016/j.clinthera.2021.10.005
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Purpose: The study objective was to explore whether prophylaxis with vitamin K-1 improves abnormal coagulation function-associated cefoperazone-sulbactam in patients treated in the long term with low-dose aspirin. Methods: This retrospective, observational study assessed patients treated with long-term low-dose aspirin in a naval military hospital in China from 2004 to 2018, including all patients treated concurrently with cefoperazone-sulbactam with or without vitamin K-1. Differences in the coagulation index were analyzed statistically before and after receipt of cefoperazone-sulbactam. Findings: The cohort included 227 patients. After cefoperazone-sulbactam treatment, the mean (SD) prothrombin time (PT) was 14.07 (3.07) seconds, activated partial thromboplastin time (aPTT) was 35.15 (4.78) seconds, and international normalized ratio (INR) was 1.49 (0.49) in the cefoperazone-sulbactam group, which was significantly higher than the PT of 11.55 (1.29), aPTT of 31.37 (2.20), and INR of 1.12 (0.35) before cefoperazone-sulbactam treatment. No significant difference was in the cefoperazone-sulbactam plus vitamin K-1 group. In addition, no significant difference was found in the thrombin time or fibrinogen level between before and after cefoperazone-sulbactam treatment in both groups. The mean (SD) platelet counts of the 2 groups were 197.34 (71.82) x 10(9)/L and 187.75 (72.66) x 1 0(9)/L after cefoperazone-sulbactam treatment, respectively, which was significantly lower than 231.77 (77.05) x 10(9)/L and 232.08 (84.48) x 10(9)/L before cefoperazone-sulbactam treatment. There were greater proportions of coagulation disorders (prolongation of PT, aPTT, INR, and bleeding) after cefoperazone-sulbactam treatment in the cefoperazone-sulbactam group compared with that in the cefoperazone-sulbactam plus vitamin K-1 group. (C) 2021 The Authors. Published by Elsevier Inc.
引用
收藏
页码:E335 / E345
页数:11
相关论文